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Background: This multicenter study aimed to create and validate a scoring system for survival of patients with
metastatic spinal cord compression (MSCC) from non-small cell lung cancer (NSCLC).
Methods: The entire cohort of 356 patients was divided in a test group (N= 178) and a validation group (N = 178).
In the test group, nine pre-treatment factors including age, gender, Eastern Cooperative Oncology Group
performance status (ECOG-PS), number of involved vertebrae, pre-radiotherapy ambulatory status, other bone
metastases, visceral metastases, interval from cancer diagnosis to radiotherapy of MSCC, and the time developing
motor were retrospectively analyzed.
Results: On multivariate analysis, survival was significantly associated with ECOG-PS, pre-radiotherapy ambulatory
status, visceral metastases, and the time developing motor deficits. These factors were included in the scoring
system; the score for each factor was determined by dividing the 6-month survival rate (in %) by 10. The risk score
represented the sum of the scores for each factor. According to the risk scores, which ranged from 6 to 19 points,
three prognostic groups were designed. The 6-month survival rates were 6% for 6–10 points, 29% for 11–15 points,
and 78% for 16–19 points (p< 0.001). In the validation group, the 6-month survival rates were 4%, 24%, and 76%,
respectively (p< 0.001).
Conclusions: Since the survival rates of the validation group were similar to those of the test group, this score can
be considered reproducible. The scoring system can help when selecting the individual treatment for patients with
MSCC from NSCLC. A prospective confirmatory study is warranted.
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Scoring systemBackground
Non-small lung cancer (NSCLC) accounts for about 15%
of all primary tumor types leading to metastatic spinal
cord compression (MSCC) [1]. Treatment options for
this oncologic emergency include different types and
programs of radiotherapy alone or, for selected patients,
upfront decompressive surgery followed by radiotherapy
[2]. Selection of the optimal treatment approach for the
individual patient should take into account the patient’s
estimated survival time. Patients with a very poor* Correspondence: rades.dirk@gmx.net
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reproduction in any medium, provided the orsurvival prognosis are generally not candidates for a bur-
densome treatment including decompressive surgery or
longer-course radiotherapy of two to four weeks. They
appear better treated with single-fraction radiotherapy
which means less discomfort for these debilitated
patients. In contrast, patients with a more favorable sur-
vival prognosis may benefit from decompressive surgery
or from longer-course radiotherapy programs, which
lead to better local control of MSCC than single-fraction
or short-course irradiation [3,4].
For optimal personalization of the treatment for each
patient with MSCC, it is critical to regard patients with
MSCC from a particular primary tumor type as a separ-
ate group of patients, because primary tumors vary withtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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present study aimed to create and validate a survival
score particularly for patients with MSCC from NSCLC,
one of the most common primary tumor types in
patients presenting with this oncologic complication.
Results
The median survival time in the entire cohort was
4 months. The patients whose data were included in this
study had been treated between 1992 and 2010. The 6-
months survival rates were 25% for patients treated until
2005 (n = 262) and 34% for patients treated after 2005
(n = 94) (p = 0.39).
In the univariate analysis of the test group, survival
was associated with the Eastern Cooperative Oncology
Group performance status (ECOG-PS), number of
involved vertebrae, pre-radiotherapy ambulatory status,
other bone metastases, visceral metastases, and the time
developing motor deficits. The results of this univariate
analysis are given in Table 1. In the multivariate analysis
of the test group, ECOG-PS, pre-radiotherapy ambula-
tory status, visceral metastases, and the time developing
motor deficits maintained significance and were
included in our scoring system. The results of the multi-
variate analysis are shown in Table 2. The scores for
each of the four significant prognostic factors obtained
from the 6-months survival rate are given in Table 3.
The addition of the four scores for each factor resulted
in total scores of 6, 9, 10, 12, 13, 15, 16, or 19 points
(Figure 1). According to the total scores, the patients of
the test group were divided into three risk groups: 6–10
points (group A, n = 79), 11–15 points (group B, n = 63),
and 16–19 points (group C, n = 36). The 6-month sur-
vival rates were 6% for group A, 29% for group B, and
78% for group C (p< 0.001, Figure 2). The 6-months
survival rates of the three risk groups of the validation
group were 4%, 24%, and 76%, respectively (p< 0.001,
Figure 3).
Discussion
Personalization of cancer treatment, which has become
more important in oncology during recent years, must
take into account the patient’s life expectancy. This
accounts in particular for a palliative situation such as
MSCC. Survival scores help estimate the survival prog-
nosis of each patient. Several scores created to estimate
the survival of patients with bone metastases already
exist. A few prognostic scores have been developed in
particular for patients with bone metastases in the verte-
bral column.
The majority of these scores were designed by to help
surgeons decide whether spinal surgery may be indicated
or not. In 1990, Tokuhashi et al. presented a score based
on the data of 64 patients with a metastatic spine tumorwho underwent spinal surgery [5]. Their score has been
revised 15 years later in a series of 246 patients [6].
Bauer et al. reported a scoring system including scoring
for pathological fracture based on the data of 88 patients
with spinal metastasis plus 153 patients with bone me-
tastasis of the extremities in 1995 [7]. Leithner et al.,
who compared different scoring systems in their series
of 69 patients in 2008, suggested a modified Bauer score
without scoring for pathological fracture [8]. The Tomita
score presented in 2001 included the data of 67 patients
[9]. Except the revised Tokuhashi score [6], these scor-
ing systems may have a limited validity due to the rela-
tively small number of patients included. Furthermore,
these scores were designed for patients with spinal me-
tastasis in general, and not particularly for patients with
motor deficits due to MSCC.
In 2005, Van der Linden et al. presented a score in a
larger series of patients (n = 342) with painful spinal me-
tastases who had received radiotherapy alone and no
surgery [10]. In that study, patients with neurologic im-
pairment were not included. All these previous scoring
systems included patients with spinal metastasis from
many different primary tumors. However, because vari-
ous primary tumor types behave differently, it is import-
ant to have separate scores for the different tumor
entities, in particular for the most common ones such as
breast cancer, prostate cancer, and NSCLC [1].
In the present study, four independent prognostic fac-
tors were found to be significantly associated with sur-
vival in patients with MSCC from NSCLC in a
comparably large series of patients. These significant fac-
tors included the ECOG-PS, pre-radiotherapy ambula-
tory status, visceral metastases, and the time developing
motor deficits. In our previous report on prognostic fac-
tors for different outcomes in the entire cohort of 356
patients, gender, other bone metastases, and the interval
from the first diagnosis of NSCLC to radiotherapy of
MSCC were also significantly associated with survival
[11]. However, we included only those prognostic factors
found to be independent in the multivariate analysis of
the test group in the present score, because we felt that
this would make the score more robust.
When compared to MSCC from other solid tumors,
patients with MSCC from NSCLC have a less favorable
estimated survival [1]. This is reflected by the fact that
the worst prognostic group, group A, was the largest
group in the present study. Based on the 6-months sur-
vival times related to the four independent prognostic
factors, three prognostic groups were formed. Group A
patients had the worst prognosis, only 6% of patients in
the test group and 4% in the validation group survived
at least 6 months following irradiation. These patients
may be considered candidates for single-fraction radio-
therapy or even best supportive care alone. Group B
Table 1 Test group: Univariate analysis of pre-treatment factors and the radiation regimen for survival
Survival Survival Median p-value
at 6 months (%) at 12 months (%) survival time (months)
Age
≤ 64 years 28 15 3
≥ 65 years 30 15 4 0.50
Gender
Female 32 29 4
Male 27 10 4 0.13
ECOG Performance status
1-2 51 26 6
3-4 15 7 3 <0.001
Number of involved vertebrae
1-2 44 28 4
≥ 3 19 4 3 <0.001
Ambulatory status prior to RT
Not Ambulatory 12 7 2
Ambulatory before RT 44 21 5 <0.001
Other bone metastases
No 45 30 4
Yes 19 4 3 <0.001
Visceral metastases
No 56 38 9
Yes 15 3 3 <0.001
Interval from cancer diagnosis to radiotherapy of MSCC
≤ 15 months 26 13 3
> 15 months 40 23 5 0.16
Time developing motor deficits
1-7 days 12 4 2
> 7 days 40 22 5 <0.001
Radiation regimen
Short-course radiotherapy 24 10 3
Longer-course radiotherapy 32 18 4 0.12
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spectively and may be treated with short-course multi-
fraction radiotherapy such as 20 Gy in 5 fractions over
one week. Short-course radiotherapy is as effective asTable 2 Test group: Multivariate analysis of pre-treatment fac
Risk ratio
ECOG Performance status 1.98
Number of involved vertebrae 1.17
Ambulatory status before radiotherapy 1.65
Other bone metastases 1.16
Visceral metastases 2.44
Time developing motor deficits 1.33longer programs with respect to post-radiotherapy
motor function [12]. In contrast, local control of MSCC
is better with longer-course than with short-course
radiotherapy [3,4]. However, local control of MSCCtors and the radiation regimen for survival
95%-confidence interval p-value
1.36 – 2.91 <0.001
0.89 – 1.56 0.27
1.05 – 2.63 0.029
0.63 – 2.10 0.63
1.66 – 3.68 <0.001
1.12 – 1.57 0.001
Table 3 Test group: 6-month survival rates and
corresponding scores
Survival Score
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Figure 2 Kaplan-Meier curves for survival of the three score
groups A (6–10 points), B (11–15 points), and C (16–19 points)
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cause most of these patients will not live long enough to
experience a local recurrence of MSCC. In contrast,
group C patients who achieved 6-months survival rates
of 78% and 76%, respectively, are at a higher risk of
developing a local recurrence of MSCC and, therefore,
are likely to benefit from longer-course radiotherapy
such as 10x3 Gy in 2 weeks or 20x2 Gy in 4 weeks. In
group B and group C patients, upfront decompressive
surgery in addition to radiotherapy may be reasonable
for selected patients with a good performance status and
involvement of only one spinal segment. This accounts
in particular for patients who are unlikely to be able to
walk after radiotherapy alone. In a randomized trial of
101 patients, decompressive surgery followed by radio-
therapy led to better pre-radiotherapy ambulatory func-
tion and survival than radiotherapy alone in such
patients [2].
The present score focused on a single tumor entity. In
contrast, previous prognostic indices for patients withFigure 1 Test group: The total scores in relation to the 6-
months survival rate (in %).vertebral metastases or other palliative situations
included many different tumor types [5-10,13-17].
Therefore, the present scoring system takes more into
account the patient’s individual situation. In order to val-
idate our score, the risk groups A, B and C of the test
group were compared to the corresponding groups A, B
and C of the validation group. The 6-months survival
rates of the three groups in the validation group proved
to be similar to the corresponding 6-months survival
rates in the test group. Thus, this new score for MSCC
from NSCLC appears valid and reproducible. However,
the score is based on retrospective data. Furthermore,
data on systemic treatment following treatment was not
available in most patients. These two aspects may have
led to a hidden selection bias. Therefore, the results of
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Figure 3 Kaplan-Meier curves for survival of the three score
groups A (6–10 points), B (11–15 points), and C (16–19 points)
from the validation group.
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The present survival score for patients with MSCC from
NSCLC was based on four independent prognostic factors
and included three prognostic groups. Patients of group A
have the worst prognosis and may be candidates for
single-fraction radiotherapy or even best supportive care
alone. Patients of group B may be treated with short-
course multi-fraction radiotherapy, and patients of group
C, who have the most favorable prognosis, appear best
treated with longer-course radiotherapy. For selected
patients of groups B and C, upfront decompressive sur-
gery in addition to radiotherapy may be considered. The
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Longer-course radiotherapyadditional scoring system taking into accout the functional
outcome following radiotherapy alone. Regarding the
score presented here, a prospective confirmatory study is
warranted.
Methods
Three-hundred-and-fifty-six unselected patients with
treated with MSCC from NSCLC were retrospectively
analyzed in this multicenter study. The patients had
received radiotherapy alone for MSCC-related motor
deficits of the legs. Patients who had prior surgery or
radiotherapy to the currently involved parts of the spinal
cord were not included. The majority of the patientsation group. The p-values were obtained from the Chi-
Test group Validation group p-value
n patients (%) n patients (%)
97 (54) 94 (53)
81 (46) 84 (47) 0.89
47 (26) 45 (25)
131 (74) 133 (75) 0.92
67 (38) 66 (37)
111 (62) 112 (63) 0.96
71 (40) 77 (43)
107 (60) 101 (57) 0.73
84 (47) 78 (44)
94 (53) 100 (56) 0.73
67 (38) 76 (43)
111 (62) 102 (57) 0.58
61 (34) 56 (31)
117 (66) 122 (69) 0.81
148 (83) 150 (84)
30 (17) 28 (16) 0.92
74 (42) 73 (41)
104 (58) 105 (59) 0.95
71 (40) 72 (40)
107 (60) 106 (60) 0.97
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mized study of Patchell et al. comparing radiotherapy
alone to decompressice surgery followed by radiotherapy
was published [2]. Of the 94 patients treated between
2006 and 2010, only 16 patients (4% of the entire co-
hort) would have met the inclusion criteria of the Patch-
ell study. Thus, the risk of a selection bias due to
excluding patients receiving surgery appears relatively
low.
Adequate diagnostic imaging including spinal CT or
spinal MRI was requested, as well as corticosteroid treat-
ment during radiotherapy. Patients were presented to a
surgeon prior to radiotherapy to discuss the option of
upfront decompressive surgery when indicated. The data
were collected from the patients, their treating physi-
cians, and the patient files. Because this study did not re-
port on a clinical trial, and because the data were
retrospective in nature and analyzed anonymously, ap-
proval by an ethic committee was not necessary. Radio-
therapy was performed with 6–10 MeV photon beams
from a linear accelerator. The treatment volumes gener-
ally encompassed one normal vertebra above and below
the involved vertebrae. One-hundred-and-forty-three
patients had received short-course radiotherapy (1x8 Gy
or 5x4 Gy in 1 week), and 213 patients were treated with
longer-course radiotherapy (10x3 Gy in 2 weeks, 14-
15x2.5 Gy in 3 weeks, or 20x2 Gy in 4 weeks).
The 356 patients were alternately assigned to the test
group (N= 178) or the validation group (N= 178). The
characteristics of both patient groups are given in
Table 4. In the test group, nine pre-treatment factors
were investigated including age (≤64 vs. ≥65 years; me-
dian age: 64 years), gender, ECOG-PS (1–2 vs. 3–4),
number of involved vertebrae (1–2 vs. ≥3), pre-
radiotherapy ambulatory status (not ambulatory vs. am-
bulatory), other bone metastases prior to radiotherapy
(no vs. yes), visceral metastases prior to radiotherapy (no
vs. yes), interval between first diagnosis of NSCLC and
radiotherapy of MSCC (≤15 vs. >15 months, in accord-
ance with previous studies), and time of developing
motor deficits prior to radiotherapy (1–7 vs. >7 days, in
accordance with previous studies). Because 69 patients
of the 194 patients (36%) who were ambulatory prior to
radiotherapy in the entire cohort had a poor ECOG-PS
of 3–4, both performance status and pre-radiotherapy
ambulatory status were investigated. In addition to these
pre-treatment factors, the potential impact of the radi-
ation regimen (short-course vs. longer-course radiother-
apy) has been investigated. The univariate analysis of
survival was performed with the Kaplan-Meier-method
and the log-rank test [18]. The significant prognostic
factors (p< 0.05) were additionally evaluated in a multi-
variate analysis performed with the Cox proportion
hazards model. The prognostic factors that weresignificant in the multivariate analysis of the test group
were included in the scoring system. The score for each
significant prognostic factor was determined by dividing
the 6-month survival rate (in %) by 10. The total score
represented the sum of the scores for each factor.
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